Dr. Marcia Angell and the Illusions of Anti-Psychiatry

Citations

1. Leucht S, Hierl S, Kissling W, Dold M, Davis JM. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry. 2012;200(2):97-106.
2. Kane JM, Cornblatt B, Correll CU, Goldberg T, Lencz T, Malhotra AK, et al. The field of schizophrenia: strengths, weaknesses, opportunities, and threats. Schizophr Bull. 2012;38(1):1-4.
3. World Health Organization. The global burden of diseasse: 2004 update. Geneva, Switzerland: WHO Press; 2008.
4. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252-60.
5. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5(2):e45.
6. Mathew SJ, Charney DS. Publication bias and the efficacy of antidepressants. Am J Psychiatry. 2009;166(2):140-5.
7. Gueorguieva R, Mallinckrodt C, Krystal JH. Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses. Arch Gen Psychiatry. 2011;68(12):1227-37.
8. Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ. Benefits From Antidepressants: Synthesis of 6-Week Patient-Level Outcomes From Double-blind Placebo-Controlled Randomized Trials of Fluoxetine and Venlafaxine. Arch Gen Psychiatry. 2012.
9. Kamlet MS, Paul N, Greenhouse J, Kupfer D, Frank E, Wade M. Cost utility analysis of maintenance treatment for recurrent depression. Control Clin Trials. 1995;16(1):17-40.
10. Katon WJ, Schoenbaum M, Fan MY, Callahan CM, Williams J, Jr., Hunkeler E, et al. Cost-effectiveness of improving primary care treatment of late-life depression. Arch Gen Psychiatry. 2005;62(12):1313-20.
11. Tournier M, Moride Y, Crott R, du Fort GG, Ducruet T. Economic impact of non-persistence to antidepressant therapy in the Quebec community-dwelling elderly population. J Affect Disord. 2009;115(1-2):160-6.
12. Vanoli A, Lane CJ, Harrison C, Steen NI, Young AH. Adequacy of venlafaxine dose prescribing in major depression and hospital resources implications. J Psychopharmacol. 2008;22(4):434-40.
13. Croghan TW, Melfi CA, Crown WE, Chawla A. Cost-effectiveness of antidepressant medications. J Ment Health Policy Econ. 1998;1(3):109-17.
14. Mitchell J, Greenberg J, Finch K, Kovach J, Kipp L, Shainline M, et al. Effectiveness and economic impact of antidepressant medications: a review. Am J Manag Care. 1997;3(2):323-30; quiz 31.
15. Miller DD, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry. 2008;193(4):279-88.
16. Satterthwaite TD, Wolf DH, Rosenheck RA, Gur RE, Caroff SN. A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. J Clin Psychiatry. 2008;69(12):1869-79.
17. Chrisphonte P, Ostroff RB, Rosenheck RA. Perphenazine Suspension: A New, Old Treatment, Side Effects and Continuous Use. Psychiatr Q. 2012.
18. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167(7):748-51.
19. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Archives of General Psychiatry. 1997;54(7):597-606.
20. Duman RS. Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression. Dialogues Clin Neurosci. 2009;11(3):239-55.

21. Malberg JE, Duman RS. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology. 2003;28(9):1562-71.
22. Magarinos AM, Deslandes A, McEwen BS. Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress. Eur J Pharmacol. 1999;371(2-3):113-22.
23. Wood GE, Young LT, Reagan LP, Chen B, McEwen BS. Stress-induced structural remodeling in hippocampus: prevention by lithium treatment. Proc Natl Acad Sci U S A. 2004;101(11):3973-8.
24. Johnson SA, Wang JF, Sun X, McEwen BS, Chattarji S, Young LT. Lithium treatment prevents stress-induced dendritic remodeling in the rodent amygdala. Neuroscience. 2009;163(1):34-9.
25. Qi H, Mailliet F, Spedding M, Rocher C, Zhang X, Delagrange P, et al. Antidepressants reverse the attenuation of the neurotrophic MEK/MAPK cascade in frontal cortex by elevated platform stress; reversal of effects on LTP is associated with GluA1 phosphorylation. Neuropharmacology. 2009;56(1):37-46.
26. Chung YC, Kim SR, Park JY, Chung ES, Park KW, Won SY, et al. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharmacology. 2011;60(6):963-74.
27. Jin Y, Lim CM, Kim SW, Park JY, Seo JS, Han PL, et al. Fluoxetine attenuates kainic acid-induced neuronal cell death in the mouse hippocampus. Brain Res. 2009;1281:108-16.
28. Kim DW, Kim DS, Kim MJ, Kwon SW, Ahn EH, Jeong HJ, et al. Imipramine enhances neuroprotective effect of PEP-1-Catalase against ischemic neuronal damage. BMB Rep. 2011;44(10):647-52.
29. Li IH, Huang WS, Shiue CY, Huang YY, Liu RS, Chyueh SC, et al. Study on the neuroprotective effect of fluoxetine against MDMA-induced neurotoxicity on the serotonin transporter in rat brain using micro-PET. Neuroimage. 2010;49(2):1259-70.
30. van Erp TG, Thompson PM, Kieseppa T, Bearden CE, Marino AC, Hoftman GD, et al. Hippocampal morphology in lithium and non-lithium-treated bipolar I disorder patients, non-bipolar co-twins, and control twins. Hum Brain Mapp. 2012;33(3):501-10.
31. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry. 2003;160(8):1516-8.
32. Yucel K, McKinnon MC, Taylor VH, Macdonald K, Alda M, Young LT, et al. Bilateral hippocampal volume increases after long-term lithium treatment in patients with bipolar disorder: a longitudinal MRI study. Psychopharmacology (Berl). 2007;195(3):357-67.
33. Malykhin NV, Carter R, Seres P, Coupland NJ. Structural changes in the hippocampus in major depressive disorder: contributions of disease and treatment. J Psychiatry Neurosci. 2010;35(5):337-43.
34. Vermetten E, Vythilingam M, Southwick SM, Charney DS, Bremner JD. Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder. Biological Psychiatry. 2003;54(7):693-702.
35. Norbury R, Taylor MJ, Selvaraj S, Murphy SE, Harmer CJ, Cowen PJ. Short-term antidepressant treatment modulates amygdala response to happy faces. Psychopharmacology (Berl). 2009;206(2):197-204.
36. Delaveau P, Jabourian M, Lemogne C, Guionnet S, Bergouignan L, Fossati P. Brain effects of antidepressants in major depression: a meta-analysis of emotional processing studies. J Affect Disord. 2011;130(1-2):66-74.
37. Harmer CJ, O'Sullivan U, Favaron E, Massey-Chase R, Ayres R, Reinecke A, et al. Effect of acute antidepressant administration on negative affective bias in depressed patients. Am J Psychiatry. 2009;166(10):1178-84.
38. Harmer CJ, Cowen PJ, Goodwin GM. Efficacy markers in depression. J Psychopharmacol. 2011;25(9):1148-58.
39. Pringle A, Browning M, Cowen PJ, Harmer CJ. A cognitive neuropsychological model of antidepressant drug action. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(7):1586-92.
40. Godlewska BR, Norbury R, Selvaraj S, Cowen PJ, Harmer CJ. Short-term SSRI treatment normalises amygdala hyperactivity in depressed patients. Psychol Med. 2012:1-9.
41. Rounsaville BJ, Klerman GL, Weissman MM. Do psychotherapy and pharmacotherapy for depression conflict? Empirical evidence from a clinical trial. Arch Gen Psychiatry. 1981;38(1):24-9.

42. Konarski JZ, Kennedy SH, Segal ZV, Lau MA, Bieling PJ, McIntyre RS, et al. Predictors of nonresponse to cognitive behavioural therapy or venlafaxine using glucose metabolism in major depressive disorder. J Psychiatry Neurosci. 2009;34(3):175-80.
43. Goldapple K, Segal Z, Garson C, Lau M, Bieling P, Kennedy S, et al. Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Arch Gen Psychiatry. 2004;61(1):34-41.
44. Mayberg HS. Defining the neural circuitry of depression: toward a new nosology with therapeutic implications. Biol Psychiatry. 2007;61(6):729-30.
45. Ressler KJ, Mayberg HS. Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci. 2007;10(9):1116-24.
46. Holtzheimer PE, Mayberg HS. Stuck in a rut: rethinking depression and its treatment. Trends Neurosci. 2011;34(1):1-9.
47. Brody AL, Saxena S, Stoessel P, Gillies LA, Fairbanks LA, Alborzian S, et al. Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. Arch Gen Psychiatry. 2001;58(7):631-40.
48. Martin SD, Martin E, Rai SS, Richardson MA, Royall R. Brain blood flow changes in depressed patients treated with interpersonal psychotherapy or venlafaxine hydrochloride: preliminary findings. Arch Gen Psychiatry. 2001;58(7):641-8.
49. Lam RW, Kennedy SH. Evidence-based strategies for achieving and sustaining full remission in depression: focus on metaanalyses. Can J Psychiatry. 2004;49(3 Suppl 1):17S-26S.
50. Rosser S, Erskine A, Crino R. Pre-existing antidepressants and the outcome of group cognitive behaviour therapy for social phobia. Aust N Z J Psychiatry. 2004;38(4):233-9.
51. Hollon SD, Jarrett RB, Nierenberg AA, Thase ME, Trivedi M, Rush AJ. Psychotherapy and medication in the treatment of adult and geriatric depression: which monotherapy or combined treatment? J Clin Psychiatry. 2005;66(4):455-68.
52. Blomhoff S, Haug TT, Hellstrom K, Holme I, Humble M, Madsbu HP, et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry. 2001;179:23-30.
53. Weissman MM. The psychological treatment of depression. Evidence for the efficacy of psychotherapy alone, in comparison with, and in combination with pharmacotherapy. Arch Gen Psychiatry. 1979;36(11):1261-9.
54. Weissman MM, Prusoff BA, Dimascio A, Neu C, Goklaney M, Klerman GL. The efficacy of drugs and psychotherapy in the treatment of acute depressive episodes. Am J Psychiatry. 1979;136(4B):555-8.
55. Thase ME, Greenhouse JB, Frank E, Reynolds CF, 3rd, Pilkonis PA, Hurley K, et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry. 1997;54(11):1009-15.
56. Reynolds CF, 3rd, Frank E, Perel JM, Imber SD, Cornes C, Miller MD, et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA. 1999;281(1):39-45.
57. Reynolds CF, 3rd, Miller MD, Pasternak RE, Frank E, Perel JM, Cornes C, et al. Treatment of bereavement-related major depressive episodes in later life: a controlled study of acute and continuation treatment with nortriptyline and interpersonal psychotherapy. Am J Psychiatry. 1999;156(2):202-8.
58. Kupfer DJ, Frank E. The interaction of drug- and psychotherapy in the long-term treatment of depression. J Affect Disord. 2001;62(1-2):131-7.
59. Lenze EJ, Dew MA, Mazumdar S, Begley AE, Cornes C, Miller MD, et al. Combined pharmacotherapy and psychotherapy as maintenance treatment for late-life depression: effects on social adjustment. Am J Psychiatry. 2002;159(3):466-8.
60. Heninger GR, Delgado PL, Charney DS. The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry. 1996;29(1):2-11.
61. Gardner A, Boles RG. Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(3):730-43.

62. Duman RS, Voleti B. Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci. 2012;35(1):47-56.
63. Sun H, Kennedy PJ, Nestler EJ. Epigenetics of the Depressed Brain: Role of Histone Acetylation and Methylation. Neuropsychopharmacology. 2012.
64. Neale BM, Kou Y, Liu L, Ma'ayan A, Samocha KE, Sabo A, et al. Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature. 2012;485(7397):242-5.
65. O'Roak BJ, Vives L, Girirajan S, Karakoc E, Krumm N, Coe BP, et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature. 2012;485(7397):246-50.
66. Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, Willsey AJ, et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature. 2012;485(7397):237-41.
67. Bergen SE, O'Dushlaine CT, Ripke S, Lee PH, Ruderfer DM, Akterin S, et al. Genome-wide association study in a Swedish population yields support for greater CNV and MHC involvement in schizophrenia compared with bipolar disorder. Mol Psychiatry. 2012.
68. Hamshere ML, Walters JT, Smith R, Richards AL, Green E, Grozeva D, et al. Genome-wide significant associations in schizophrenia to ITIH3/4, CACNA1C and SDCCAG8, and extensive replication of associations reported by the Schizophrenia PGC. Mol Psychiatry. 2012.
69. Lewis DA, Sweet RA. Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies. J Clin Invest. 2009;119(4):706-16.
70. Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012;62(1):63-77.
71. Rajkowska G, Miguel-Hidalgo JJ. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets. 2007;6(3):219-33.
72. Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proceedings of the National Academy of Sciences of the United States of America. 1998;95(22):13290-5.
73. Laakso A, Vilkman H, Alakare B, Haaparanta M, Bergman J, Solin O, et al. Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. Am J Psychiatry. 2000;157(2):269-71.
74. McCreadie RG, Padmavati R, Thara R, Srinivasan TN. Spontaneous dyskinesia and parkinsonism in never-medicated, chronically ill patients with schizophrenia: 18-month follow-up. Br J Psychiatry. 2002;181:135-7.
75. Hietala J, Cannon TD, van Erp TG, Syvalahti E, Vilkman H, Laakso A, et al. Regional brain morphology and duration of illness in never-medicated first-episode patients with schizophrenia. Schizophr Res. 2003;64(1):79-81.
76. Ludewig K, Geyer MA, Vollenweider FX. Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia. Biol Psychiatry. 2003;54(2):121-8.
77. Valkonen-Korhonen M, Purhonen M, Tarkka IM, Sipila P, Partanen J, Karhu J, et al. Altered auditory processing in acutely psychotic never-medicated first-episode patients. Brain Res Cogn Brain Res. 2003;17(3):747-58.
78. Brickman AM, Buchsbaum MS, Bloom R, Bokhoven P, Paul-Odouard R, Haznedar MM, et al. Neuropsychological functioning in first-break, never-medicated adolescents with psychosis. J Nerv Ment Dis. 2004;192(9):615-22.
79. Sanders RD, Schuepbach D, Goldstein G, Haas GL, Sweeney JA, Keshavan MS. Relationships between cognitive and neurological performance in neuroleptic-naive psychosis. J Neuropsychiatry Clin Neurosci. 2004;16(4):480-7.
80. MacDonald AW, 3rd, Carter CS, Kerns JG, Ursu S, Barch DM, Holmes AJ, et al. Specificity of prefrontal dysfunction and context processing deficits to schizophrenia in never-medicated patients with first-episode psychosis. Am J Psychiatry. 2005;162(3):475-84.
81. Snitz BE, MacDonald A, 3rd, Cohen JD, Cho RY, Becker T, Carter CS. Lateral and medial hypofrontality in first-episode schizophrenia: functional activity in a medication-naive state and effects of short-term atypical antipsychotic treatment. Am J Psychiatry. 2005;162(12):2322-9.

82. Chua SE, Cheung C, Cheung V, Tsang JT, Chen EY, Wong JC, et al. Cerebral grey, white matter and csf in never-medicated, first-episode schizophrenia. Schizophr Res. 2007;89(1-3):12-21.
83. Cheung V, Cheung C, McAlonan GM, Deng Y, Wong JG, Yip L, et al. A diffusion tensor imaging study of structural dysconnectivity in never-medicated, first-episode schizophrenia. Psychol Med. 2008;38(6):877-85.
84. Hurlemann R, Jessen F, Wagner M, Frommann I, Ruhrmann S, Brockhaus A, et al. Interrelated neuropsychological and anatomical evidence of hippocampal pathology in the at-risk mental state. Psychol Med. 2008;38(6):843-51.
85. Cheung V, Chiu CP, Law CW, Cheung C, Hui CL, Chan KK, et al. Positive symptoms and white matter microstructure in never-medicated first episode schizophrenia. Psychol Med. 2011;41(8):1709-19.
86. Mandl RC, Rais M, van Baal GC, van Haren NE, Cahn W, Kahn RS, et al. Altered white matter connectivity in never-medicated patients with schizophrenia. Hum Brain Mapp. 2012.
87. MacMaster FP, Russell A, Mirza Y, Keshavan MS, Taormina SP, Bhandari R, et al. Pituitary volume in treatment-naive pediatric major depressive disorder. Biol Psychiatry. 2006;60(8):862-6.
88. Ma N, Li L, Shu N, Liu J, Gong G, He Z, et al. White matter abnormalities in first-episode, treatment-naive young adults with major depressive disorder. Am J Psychiatry. 2007;164(5):823-6.
89. Matsuo K, Rosenberg DR, Easter PC, MacMaster FP, Chen HH, Nicoletti M, et al. Striatal volume abnormalities in treatment-naive patients diagnosed with pediatric major depressive disorder. J Child Adolesc Psychopharmacol. 2008;18(2):121-31.
90. Zhu X, Wang X, Xiao J, Zhong M, Liao J, Yao S. Altered white matter integrity in first-episode, treatment-naive young adults with major depressive disorder: a tract-based spatial statistics study. Brain Res. 2011;1369:223-9.
91. Hajek T, Cullis J, Novak T, Kopecek M, Hoschl C, Blagdon R, et al. Hippocampal volumes in bipolar disorders: opposing effects of illness burden and lithium treatment. Bipolar Disord. 2012;14(3):261-70.
92. Tao R, Calley CS, Hart J, Mayes TL, Nakonezny PA, Lu H, et al. Brain activity in adolescent major depressive disorder before and after fluoxetine treatment. Am J Psychiatry. 2012;169(4):381-8.
93. Wang Y, Jia Y, Xu G, Ling X, Liu S, Huang L. Frontal white matter biochemical abnormalities in first-episode, treatment-naive patients with major depressive disorder: a proton magnetic resonance spectroscopy study. J Affect Disord. 2012;136(3):620-6.
94. Zhu X, Wang X, Xiao J, Liao J, Zhong M, Wang W, et al. Evidence of a dissociation pattern in resting-state default mode network connectivity in first-episode, treatment-naive major depression patients. Biol Psychiatry. 2012;71(7):611-7.
95. Callicott JH, Egan MF, Bertolino A, Mattay VS, Langheim FJ, Frank JA, et al. Hippocampal N-acetyl aspartate in unaffected siblings of patients with schizophrenia: a possible intermediate neurobiological phenotype. Biol Psychiatry. 1998;44(10):941-50.
96. Callicott JH, Egan MF, Mattay VS, Bertolino A, Bone AD, Verchinksi B, et al. Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia. Am J Psychiatry. 2003;160(4):709-19.
97. Honea RA, Meyer-Lindenberg A, Hobbs KB, Pezawas L, Mattay VS, Egan MF, et al. Is gray matter volume an intermediate phenotype for schizophrenia? A voxel-based morphometry study of patients with schizophrenia and their healthy siblings. Biol Psychiatry. 2008;63(5):465-74.
98. Mamah D, Harms MP, Wang L, Barch D, Thompson P, Kim J, et al. Basal ganglia shape abnormalities in the unaffected siblings of schizophrenia patients. Biol Psychiatry. 2008;64(2):111-20.
99. Meda SA, Bhattarai M, Morris NA, Astur RS, Calhoun VD, Mathalon DH, et al. An fMRI study of working memory in first-degree unaffected relatives of schizophrenia patients. Schizophr Res. 2008;104(1-3):85-95.
100. Mattai A, Hosanagar A, Weisinger B, Greenstein D, Stidd R, Clasen L, et al. Hippocampal volume development in healthy siblings of childhood-onset schizophrenia patients. Am J Psychiatry. 2011;168(4):427-35.
101. Kruger S, Alda M, Young LT, Goldapple K, Parikh S, Mayberg HS. Risk and resilience markers in bipolar disorder: brain responses to emotional challenge in bipolar patients and their healthy siblings. Am J Psychiatry. 2006;163(2):257-64.

102. Trivedi JK, Goel D, Dhyani M, Sharma S, Singh AP, Sinha PK, et al. Neurocognition in first-degree healthy relatives (siblings) of bipolar affective disorder patients. Psychiatry Clin Neurosci. 2008;62(2):190-6.
103. Glahn DC, Almasy L, Barguil M, Hare E, Peralta JM, Kent JW, Jr., et al. Neurocognitive endophenotypes for bipolar disorder identified in multiplex multigenerational families. Arch Gen Psychiatry. 2010;67(2):168-77.
104. Kulkarni S, Jain S, Janardhan Reddy YC, Kumar KJ, Kandavel T. Impairment of verbal learning and memory and executive function in unaffected siblings of probands with bipolar disorder. Bipolar Disord. 2010;12(6):647-56.
105. Almeida KM, Nery FG, Moreno RA, Gorenstein C, Lafer B. Personality traits in bipolar disorder type I: a sib-pair analysis. Bipolar Disord. 2011;13(7-8):662-9.
106. Berger S, Schulz S, Kletta C, Voss A, Bar KJ. Autonomic modulation in healthy first-degree relatives of patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(7):1723-8.
107. Walton E, Turner J, Gollub RL, Manoach DS, Yendiki A, Ho BC, et al. Cumulative Genetic Risk and Prefrontal Activity in Patients With Schizophrenia. Schizophr Bull. 2012.
108. Rasetti R, Sambataro F, Chen Q, Callicott JH, Mattay VS, Weinberger DR. Altered cortical network dynamics: a potential intermediate phenotype for schizophrenia and association with ZNF804A. Arch Gen Psychiatry. 2011;68(12):1207-17.
109. Voineskos AN, Lett TA, Lerch JP, Tiwari AK, Ameis SH, Rajji TK, et al. Neurexin-1 and frontal lobe white matter: an overlapping intermediate phenotype for schizophrenia and autism spectrum disorders. PLoS ONE. 2011;6(6):e20982.
110. Erk S, Meyer-Lindenberg A, Schnell K, Opitz von Boberfeld C, Esslinger C, Kirsch P, et al. Brain function in carriers of a genome-wide supported bipolar disorder variant. Arch Gen Psychiatry. 2010;67(8):803-11.
111. Glahn DC, Curran JE, Winkler AM, Carless MA, Kent JW, Jr., Charlesworth JC, et al. High dimensional endophenotype ranking in the search for major depression risk genes. Biol Psychiatry. 2012;71(1):6-14.
112. Hoffman RE. Auditory/Verbal hallucinations, speech perception neurocircuitry, and the social deafferentation hypothesis. Clin EEG Neurosci. 2008;39(2):87-90.
113. Ford JM, Mathalon DH. Corollary discharge dysfunction in schizophrenia: can it explain auditory hallucinations? Int J Psychophysiol. 2005;58(2-3):179-89.
114. van Lutterveld R, Sommer IE, Ford JM. The neurophysiology of auditory hallucinations - a historical and contemporary review. Front Psychiatry. 2011;2:28.
115. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry. 2003;160(1):13-23.
116. Corlett PR, Taylor JR, Wang XJ, Fletcher PC, Krystal JH. Toward a Neurobiology of Delusions. Prog Neurobiol. 2010.
117. Roiser JP, Elliott R, Sahakian BJ. Cognitive mechanisms of treatment in depression. Neuropsychopharmacology. 2012;37(1):117-36.
118. Phelps EA, LeDoux JE. Contributions of the amygdala to emotion processing: from animal models to human behavior. Neuron. 2005;48(2):175-87.
119. Davis M. Neural systems involved in fear and anxiety measured with fear-potentiated startle. Am Psychol. 2006;61(8):741-56.
120. Gross CP, Anderson GF, Powe NR. The relation between funding by the National Institutes of Health and the burden of disease. New England Journal of Medicine. 1999;340(24):1881-7.
121. Ben-Noun L. Characterization of patients refusing professional psychiatric treatment in a primary care clinic. Isr J Psychiatry Relat Sci. 1996;33(3):167-74.